文献速递类风湿关节炎

牙周炎及牙周治疗对类风湿关节炎结局的影响:一项探索性临床试验

The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项探索性随机延迟启动研究纳入22例伴中重度牙周炎的类风湿关节炎患者,全口清创后随访至6个月。基线时重度牙周炎患者RA疾病活动度显著高于中度者;牙周治疗后仅重度牙周炎患者DAS28显著改善且抗CCP2 IgG水平显著下降。作者认为牙周评估与治疗应纳入RA的达标治疗管理。

要点

  • 基线时重度牙周炎RA患者疾病活动度显著高于中度牙周炎患者。
  • 牙周治疗后仅重度牙周炎患者DAS28显著改善(ΔV2-V1 P=0.042;ΔV3-V1 P=0.001)。
  • 重度牙周炎患者V3时抗CCP2 IgG水平显著下降(P=0.032)。

核心结论

  • 牙周治疗在RA患者中局部有效,并在重度牙周炎患者中影响RA疾病活动度和抗CCP2抗体水平。
  • 作者认为牙周评估和治疗应纳入RA患者的达标治疗管理。

研究设计与样本

  • 探索性随机延迟启动研究,纳入22例伴中度或重度牙周炎的RA患者,接受全口清创。
  • 在牙周治疗第1步和第2步后基线(V1)、2个月(V2)和6个月(V3)进行牙周和风湿病学评估,包括检测抗环瓜氨酸肽2(CCP2)IgG水平。
  • 主要结局为V2与V1之间28关节DAS(DAS28)的变化,次要结局为其他风湿病学或牙周临床参数的变化(V2或V3减V1)。

主要发现

  • 基线时重度牙周炎RA患者疾病活动度显著高于中度牙周炎患者,多个风湿病学与牙周参数间呈显著正相关。
  • 牙周治疗后,重度牙周炎RA患者DAS28显著改善(ΔV2-V1,P=0.042;ΔV3-V1,P=0.001),中度牙周炎患者未见显著改善。
  • 重度牙周炎RA患者V3时抗CCP2 IgG水平显著下降(P=0.032)。

关键数值与推荐

  • 主要结局为V2与V1之间DAS28的变化。
  • 重度牙周炎患者DAS28变化:ΔV2-V1,P=0.042;ΔV3-V1,P=0.001。
  • 重度牙周炎患者V3时抗CCP2 IgG水平下降,P=0.032。

临床怎么用

  • 作者认为牙周评估和治疗应纳入RA患者的达标治疗管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Studies suggest RA patients could benefit from periodontal treatment. However, published data are inconsistent, and there is a need for better-controlled research. Our study aims to address these limitations. METHODS: In this exploratory randomized delayed-start study, 22 RA patients with moderate/severe periodontitis were subjected to full-mouth debridement. Periodontal and rheumatological assessments, including measuring anti-cyclic citrullinated peptide 2 (CCP2) IgG levels, were performed at baseline (V1), 2 months (V2) and 6 months (V3) after steps 1 and 2 of periodontal therapy. Primary outcome was changes in DAS for 28 joints (DAS28) between V2 and V1. Secondary outcomes were changes in other rheumatological or periodontal clinical parameters (V2 or V3-V1). RESULTS: RA disease activity was significantly higher in RA patients with severe periodontitis compared with moderate periodontitis at baseline, with significant positive correlations between several rheumatological and periodontal parameters. After periodontal treatment, RA patients with severe, but not moderate, periodontitis demonstrated significant improvements in DAS28 (ΔV2-V1, P = 0.042; ΔV3-V1, P = 0.001) and significant reduction in anti-CCP2 IgG levels at V3 (P = 0.032). CONCLUSION: Periodontal treatment is locally effective in patients with RA and impacts RA disease activity and anti-CCP2 antibody levels in patients with severe periodontitis. Hence, our data suggest that periodontal assessment and treatment should be integrated in the management of RA patients within a treat-to-target strategy. TRIAL REGISTRATION: isrctn.com, http://www.isrctn.com, ISRCTN 17950307.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Silva DS, de Vries C, Rovisco J, et al. The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial. Rheumatology (Oxford). 2025. PMID: 39002123. doi:10.1093/rheumatology/keae358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。